Audentes Set To Resume XLMTM Trial As US Hold Lifts
Talks With Regulators On Way Forward
Trial of high-need gene therapy set to restart following the deaths of several participants and the lifting of a clinical hold imposed by the US FDA last year.
You may also be interested in...
The day before an FDA advisory committee meeting about the safety of AAV vector-based gene therapies, Astellas reported liver damage in a patient in its trial of AT132.
Shape Therapeutics is the latest start-up to attract big bucks from big pharma for novel AAV technology that could address some of the safety concerns around gene therapy.
Several companies have recently raised large amounts of money from venture capital as well as potentially through partnerships for next-generation capsid technology.